ERSP gives Swiss Labs go-ahead with changes
This article was originally published in The Tan Sheet
The Electronic Retailing Self-Regulation Program gives thumbs up to Swiss Labs for substantiating most claims for its Arthi-Zen Relief Dietary Supplement, but asks the firm to modify certain statements. ERSP says July 9 the marketer's clinical study supported general efficacy claims for the reduction of joint and muscle discomfort, but asks the firm to remove mention of "clinical studies" because there is only one. The group also asked Swiss Labs to modify the "immediate" relief claim because the study suggested most saw improvement after four days, and to modify the context of the claim "24-Hour Joint Relief" to explain that users "can experience relief for up to 24 hours in between dosages." Swiss Labs said it will comply. ERSP reviewed the Kankakee, Ill.-based firm's ads in ongoing monitoring
You may also be interested in...
Complex active ingredients, formulations, routes of delivery, and drug-device combination products are to receive greater attention as part of attempts to facilitate competition after the US FDA awarded a $5m grant to establish a dedicated research center.
In October, the period during which Mylan may complete its merger with Upjohn will begin, while the FDA will begin holding monthly stakeholder meetings ahead of the third iteration of the Generic Drug User Fee Amendments program, also known as GDUFA III.
The UK life sciences trade group says the “ill-considered” guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.